Immune response of primary and booster immunity of SARS-CoV-2 vaccination among patients with chronic liver disease
Abstract Aim we examined the humoral immune response and antibody dynamics after primary and booster vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among patients with chronic liver disease (CLD).Methods We enrolled patients with confirmed CLD and SARS-CoV-2 vaccination primary or booster immunity. Following primary or booster immunity, serological samples were gathered to detect novel coronavirus neutralizing antibodies (nCoV NTAb) and novel coronavirus spike receptor-binding proteins (nCoV S-RBD).Results The positive rate of nCoV NTAb was 60.1% in Primary and 87.6% in Booster (P<0.001). The median level of nCoV NTAb was 11.6 AU/mL in Primary and 31.6 AU/mL in Booster (P<0.001). The positive rate of nCoV S-RBD was 70.0% in Primary and 91.2% in Booster (P<0.001). The median level of nCoV S-RBD was 21.7 AU/mL in Primary and 110.6 AU/mL in Booster (P<0.001). Compared to the antibody level of primary immunity, 21 patients in whom SARS-CoV-2 vaccine antibodies were detected after both primary and booster immunizations showed an increase of 4.4 and 5.9 times in nCoV NTAb and nCoV S-RBD, respectively.Conclusion Patients with CLD show improved humoral immune response after completing primary and booster immunity of SARS-CoV-2 vaccines, while booster immunity further improves the positive rate and antibody level of patients with CLD..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 30. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Song, Ruixin [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.11.12.22282242 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI037880012 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI037880012 | ||
| 003 | DE-627 | ||
| 005 | 20231201090747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221116s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.11.12.22282242 |2 doi | |
| 035 | |a (DE-627)XBI037880012 | ||
| 035 | |a (biorXiv)10.1101/2022.11.12.22282242 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Song, Ruixin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune response of primary and booster immunity of SARS-CoV-2 vaccination among patients with chronic liver disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Aim we examined the humoral immune response and antibody dynamics after primary and booster vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among patients with chronic liver disease (CLD).Methods We enrolled patients with confirmed CLD and SARS-CoV-2 vaccination primary or booster immunity. Following primary or booster immunity, serological samples were gathered to detect novel coronavirus neutralizing antibodies (nCoV NTAb) and novel coronavirus spike receptor-binding proteins (nCoV S-RBD).Results The positive rate of nCoV NTAb was 60.1% in Primary and 87.6% in Booster (P<0.001). The median level of nCoV NTAb was 11.6 AU/mL in Primary and 31.6 AU/mL in Booster (P<0.001). The positive rate of nCoV S-RBD was 70.0% in Primary and 91.2% in Booster (P<0.001). The median level of nCoV S-RBD was 21.7 AU/mL in Primary and 110.6 AU/mL in Booster (P<0.001). Compared to the antibody level of primary immunity, 21 patients in whom SARS-CoV-2 vaccine antibodies were detected after both primary and booster immunizations showed an increase of 4.4 and 5.9 times in nCoV NTAb and nCoV S-RBD, respectively.Conclusion Patients with CLD show improved humoral immune response after completing primary and booster immunity of SARS-CoV-2 vaccines, while booster immunity further improves the positive rate and antibody level of patients with CLD. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Yang, Chao |4 aut | |
| 700 | 1 | |a Wang, Jiayin |4 aut | |
| 700 | 1 | |a Li, Qianqian |4 aut | |
| 700 | 1 | |a Chen, Jing |4 aut | |
| 700 | 1 | |a Sun, Kai |4 aut | |
| 700 | 1 | |a Lv, Hongmin |4 aut | |
| 700 | 1 | |a Yang, Yankai |4 aut | |
| 700 | 1 | |a Liang, Jing |4 aut | |
| 700 | 1 | |a Ye, Qing |4 aut | |
| 700 | 1 | |a Gao, YanYing |4 aut | |
| 700 | 1 | |a Li, Jun |4 aut | |
| 700 | 1 | |a Li, Ying |4 aut | |
| 700 | 1 | |a Yan, Junqing |4 aut | |
| 700 | 1 | |a Liu, Ying |4 aut | |
| 700 | 1 | |a Wang, Tao |4 aut | |
| 700 | 1 | |a Liu, Changen |4 aut | |
| 700 | 1 | |a Wang, Fei |4 aut | |
| 700 | 1 | |a Yin, Weili |4 aut | |
| 700 | 1 | |a Xiang, Huiling |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 30. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:30 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.11.12.22282242 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 30 |c 11 | ||